This study demonstrates that miR-21 regulates injury in hypoxic cardiomyocytes, indicating its potential as a biomarker and therapeutic target for myocardial infarction.
Key Points
Inhibition of miR-21 significantly reduced cellular apoptosis rates in H9c2 cells exposed to hypoxia.
Plasma levels of miR-21, miR-488, and miR-126 effectively differentiated NSTEMI and STEMI patients from healthy individuals.
Higher levels of plasma miR-21 in older STEMI patients suggest its role in aging and myocardial infarction.
Targeting Smad-7 with miR-21 offers a promising therapeutic approach for managing AMI.